Related Experiment Video
Updated: Feb 4, 2026

Laser-Induced Chronic Ocular Hypertension Model on SD Rats
Published on: December 4, 2007
Lipoxin B4 Mitigates TRPV4-Activated Müller Cell Gliosis During Ocular Hypertension
Matangi Kumar1,2, Shruthi Karnam2, Shubham Maurya2
1Vision Science Graduate Group, University of California Berkeley, Berkeley, California, United States.
Purpose:
Müller glia play dual roles in glaucoma, contributing to retinal homeostasis and neuroinflammation; activation by elevated intraocular pressure through mechanosensitive transient receptor potential vanilloid 4 (TRPV4) promotes a reactive state that drives retinal ganglion cell loss. Lipoxin B4 (LXB4), an endogenous lipid mediator produced by retinal astrocytes, suppresses glial reactivity and protects retinal ganglion cells. This study investigated whether LXB4 modulates TRPV4-driven Müller glial activation and whether Müller glia contribute to the lipoxin pathway.
Methods:
Ocular hypertension was induced in mice via a silicone oil model, and reactive Müller glia were isolated by magnetic sorting for transcriptomics. In vitro, Müller glia cultures were treated with a TRPV4 agonist with or without LXB4. Glial reactivity was assessed by flow cytometry, immunostaining, qPCR, and Western blotting. Lipidomics quantified pathway metabolites, and single-cell RNA sequencing examined transcriptional responses to LXB4.
Results:
Bulk RNA sequencing and qPCR revealed Müller glia express 5- and 15-lipoxygenase. Lipidomics confirmed a functional pathway, with endogenous LXB4 production, identifying Müller glia as a source of neuroprotective LXB4. TRPV4 activation induced gliosis with increased glial fibrillary acidic protein, IL-6, and signal transducers and activators of transcription 3 (STAT3) expression, and lipoxin production, indicating biomechanical stress triggers reactivity and protective signaling. LXB4 suppressed TRPV4-induced gliosis in vitro by downregulating IL-6 and STAT3 and in vivo by reducing Stat3, Il6, and Tnf-α and attenuating TRPV4 upregulation during ocular hypertension.
Conclusions:
Müller glia are a significant source of LXB4 in the retina. This neuroprotective Müller glia pathway is amplified during chronic TRPV4 activation to counter-regulate gliosis. These findings support the targeting of the TRPV4-lipoxin pathway as a potential approach to protect against ocular hypertension-induced neurodegeneration in glaucoma.
Insights
Müller glia produce lipoxin B4 (LXB4), a neuroprotective mediator that suppresses glial reactivity. This study shows LXB4 counter-regulates TRPV4-induced Müller glia activation, offering a potential glaucoma treatment target.
Area of Science:
- Neuroscience
- Ophthalmology
- Cell Biology
Background:
- Müller glia are crucial for retinal homeostasis but contribute to neuroinflammation in glaucoma.
- Elevated intraocular pressure activates Müller glia via TRPV4 channels, leading to retinal ganglion cell loss.
- Lipoxin B4 (LXB4), produced by astrocytes, can suppress glial reactivity and protect retinal ganglion cells.
Purpose of the Study:
- To investigate if LXB4 modulates TRPV4-mediated Müller glia activation.
- To determine if Müller glia contribute to the lipoxin pathway.
Main Methods:
- Induction of ocular hypertension in mice.
- Isolation of reactive Müller glia for transcriptomic analysis.
- In vitro treatment of Müller glia cultures with TRPV4 agonist and LXB4.
- Assessment of glial reactivity using flow cytometry, immunostaining, qPCR, and Western blotting.
- Lipidomics and single-cell RNA sequencing to analyze pathway metabolites and transcriptional responses.
Main Results:
- Müller glia express 5- and 15-lipoxygenase, producing endogenous LXB4.
- TRPV4 activation induced gliosis, increasing GFAP, IL-6, and STAT3 expression, and lipoxin production.
- LXB4 suppressed TRPV4-induced gliosis in vitro and in vivo by downregulating inflammatory markers and attenuating TRPV4 upregulation.
Conclusions:
- Müller glia are a significant source of the neuroprotective mediator LXB4.
- The LXB4 pathway in Müller glia is amplified during TRPV4 activation to counteract gliosis.
- Targeting the TRPV4-lipoxin pathway presents a potential therapeutic strategy for glaucoma.
Related Concept Videos
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension V: Nursing Management
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Hypertension and Regulation of Blood Pressure
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

